anonymous
Guest
anonymous
Guest
So we find ourselves about a month away from our next review of Javelin for our 4Q targeting. Why don't we just cut to the chase right now...if you don't process (and NOT REJECT) every action request in Veeva, why even send a new Javelin panel to us. It seems we are constantly asked to call on ghosts, corpses and no see drs, while the drs we add which have displaced the former are neglected for data purposes, leaving us wondering if we are having any impact. Nathan and Lou, its incumbent upon you to rattle the cage of data operations if you want better, more accurate results. The complaints to managers have fallen on deaf ears. The biggest problem in pharma are the stuffed shirt desk jockeys thinking they understand things better than the people actually doing the work. JV was full of shit, his belief on data has not resulted in the projected results. If anything, he was fooled by the data, which was the result of unscrupulous reps and managers. Checks and balances would have clarified the fraud and focused us on the proper course.